glp-1 drugs eli lilly Novo, weight-loss should be first option obesity treatments, European doctors say Novo Nordisk, Eli Lilly roll
Description
Endocrinology 119 (4), 14671475
Both drug classes demonstrate cardiovascular benefits, with SGLT2 inhibitors particularly effective for heart failure and GLP-1 receptor agonists reducing major adverse cardiovascular events
10.2337/dci18-0033 34 DavisJ.SinghS.SethiS.RoyS.MittraS.RayasamG.et al (2010)
Di Mauro S et al
Their GLP-1 Plus Program provides access to clinical weight loss medications like tirzepatide
[13] Neither the participant nor the health care provider knew which treatment was being given until after the trials were completed
